Clinical Trial Detail

NCT ID NCT02636036
Title Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors PsiOxus Therapeutics Ltd
Indications

salivary gland cancer

head and neck squamous cell carcinoma

bladder carcinoma

colorectal cancer

Therapies

Enadenotucirev + Pembrolizumab

Age Groups: adult

No variant requirements are available.